Welcome to our dedicated page for TPTX news (Ticker: TPTX), a resource for investors and traders seeking the latest updates and insights on TPTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TPTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TPTX's position in the market.
Turning Point Therapeutics reported initial data from the Phase 1/2 SWORD-1 study of its RET inhibitor TPX-0046. Tumor regression was observed in 4 of 5 TKI-naïve patients, including 2 confirmed partial responses. The trial also showed tumor regression in 3 of 9 TKI-pretreated patients. The drug was generally well tolerated, with dizziness as the most common side effect. The company plans to expand the study with additional cohorts following the dose finding phase. This study addresses unmet needs in RET-driven cancers, impacting nearly 10,000 patients annually in the U.S. and E.U.
Turning Point Therapeutics (NASDAQ: TPTX) announces the appointment of Barbara Bodem to its board of directors as Chair of the Audit Committee. Bodem, with over 30 years of experience, previously held key finance roles at major companies and is currently CFO at Hill-Rom Holdings. Garry Nicholson has been named interim Board Chair following the departure of Sheila Gujrathi and Jacob Chacko. Turning Point is progressing in precision oncology, continuing to develop innovative therapies targeting cancer's genetic drivers.
Turning Point Therapeutics (NASDAQ: TPTX) announced four abstracts showcasing its drug candidates at the AACR annual meeting from April 10-14, 2021. Key highlights include repotrectinib's preclinical combination data with MEK inhibitors and its potency against TRK fusion proteins. The company will also present data on TPX-0022's utility with immune checkpoint inhibitors and TPX-0131’s efficacy against ALK resistance mutations. These presentations could provide insights into the drugs' potential market impact and clinical applications.
Turning Point Therapeutics (NASDAQ: TPTX) has announced its participation in key investor conferences in March 2021. On March 9, President and CEO Athena Countouriotis will present at the H.C. Wainwright Global Life Sciences Conference at 7 a.m. ET. On March 17, CFO Yi Larson will present at the Oppenheimer 31st Annual Healthcare Conference at 1:50 p.m. ET, followed by Dr. Countouriotis participating in a fireside chat and panel discussion at the 33rd Annual Roth Conference. All sessions will be available via webcast on the company's investors page.
Turning Point Therapeutics reported strong operational progress and financial results for Q4 and full year 2020. Key highlights include completion of 50 patient enrollment in the TRIDENT-1 study, with a confirmed objective response rate of 93% in a subset of patients. The company holds $1.1 billion in cash, expected to fund operations into 2024. Upcoming milestones include FDA meetings and clinical updates in 2021 for pipeline candidates like repotrectinib and TPX-0022. A net loss of $47.4 million was recorded for Q4, up from $21 million a year prior.
Turning Point Therapeutics (NASDAQ: TPTX) will announce its financial results for Q4 and the year ending December 31, 2020, on March 1, 2021, after U.S. markets close. A conference call will be held at 1:30 p.m. PT/4:30 p.m. ET, led by President and CEO Athena Countouriotis, M.D. The call will include operational updates and a Q&A session. Participants can join via audio webcast on the company's website or by phone. The company focuses on precision oncology, with its lead candidate repotrectinib targeting ROS1 and TRK drivers in cancer.
Turning Point Therapeutics (NASDAQ: TPTX) announced participation in the Guggenheim Healthcare Talks 2021 Oncology Days on Feb. 11-12. CEO Athena Countouriotis, M.D. will engage in two Q&A sessions: a joint discussion with Zai Lab on Feb. 12 at 8:30 a.m. ET and a company-focused discussion at 11:00 a.m. ET. The sessions can be accessed via webcast on www.tptherapeutics.com. Turning Point specializes in precision oncology with investigational drugs targeting genetic drivers of cancer, including its lead candidate, repotrectinib.
Turning Point Therapeutics (TPTX) announced promising interim results from the TRIDENT-1 trial for repotrectinib in ROS1-positive, TKI-naïve non-small cell lung cancer (NSCLC). The Phase 2 confirmed objective response rate (ORR) reached 93% (95% CI: 68-100), while the pooled Phase 1/2 ORR was 91% (95% CI: 71-99). Currently, around 40 patients are enrolled. The company aims to meet with the FDA in the first half of 2021 to discuss the drug's regulatory path.
Turning Point Therapeutics (TPTX) announced significant milestones for 2021, including updated data from the TRIDENT-1 study on ROS1-positive non-small cell lung cancer, scheduled for January 31 at the World Conference on Lung Cancer. The company plans to submit its fourth drug candidate IND in Q1 and initiate combination studies for repotrectinib and TPX-0022. As of December 31, 2020, it holds approximately $1.1 billion in cash to fund operations into 2024. The CEO expressed confidence in advancing their pipeline amid regulatory feedback.
Turning Point Therapeutics has expanded its partnership with Zai Lab, granting exclusive rights to develop and commercialize TPX-0022 in Greater China. This agreement includes a $25 million upfront payment and potential milestone payments of approximately $336 million, along with royalties based on sales. The collaboration builds on an existing agreement for another drug candidate. Initial data from the Phase 1 SHIELD-1 study shows promising results for TPX-0022 in treating MET-driven cancers, particularly in gastric and lung cancer.
FAQ
What is the market cap of TPTX (TPTX)?
